2-(4-哌啶基甲基)吡啶二盐酸盐 | 886886-02-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(4-哌啶基甲基)吡啶二盐酸盐
• 中文别名: 2-(哌啶-4-基甲基)吡啶二盐酸盐
• 英文名称: 2-(Piperidin-4-ylmethyl)pyridine dihydrochloride
• 英文别名: 2-(piperidin-4-ylmethyl)pyridine;dihydrochloride
• CAS: 886886-02-8
• 化学式: C11H18Cl2N2
• 分子量: 249.18
• InChiKey: VJRYOBIUFQEAHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.47
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  24.9
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

文献信息

• N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS
  申请人：BABIN Didier

  公开号：US20100093668A1

  公开（公告）日：2010-04-15

  The disclosure relates to a compound of formula (I): wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditions capable of being modulated by the inhibition of the activity of protein kinases.

  该披露涉及到一个式（I）的化合物： 其中R、R1、R2、R3、R4、R5、R6和Z如规范中所定义，以及包含它们的组合物，制备它们的过程，以及它们在治疗或预防能够通过抑制蛋白激酶活性而调节的疾病中的使用。
• [EN] TRAF 6 INHIBITORS<br/>[FR] INHIBITEURS DE TRAF 6
  申请人：HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH

  公开号：WO2018050286A1

  公开（公告）日：2018-03-22

  The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds.

  本发明涉及适用于治疗癌症、免疫性疾病、帕金森病、心脏肥大或2型糖尿病的化合物，以及含有这些化合物的药物组合物。该发明还涉及包含这些化合物的配套工具包。
• PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS
  申请人：Baker Stewart James

  公开号：US20100016306A1

  公开（公告）日：2010-01-21

  Thienopyrimidines of formula (Ia) or (Ib): wherein R 1 -R 3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  式(Ia)或(Ib)的噻唑并[3,2-d]嘧啶类化合物：其中R1-R3具有以下任何一种所述的值，以及其药学上可接受的盐具有PI3K抑制剂活性，因此可用于治疗由于PI3激酶异常细胞生长、功能或行为引起的疾病和障碍，特别是p110 delta亚型，例如免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经障碍。还描述了合成该化合物的方法。
• NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES
  申请人：Cheng Hengmiao

  公开号：US20090093463A1

  公开（公告）日：2009-04-09

  The present invention relates to compounds with the formula (I) or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of 11-β-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I).

  本发明涉及公式(I)的化合物或其药学上可接受的盐：该发明还涉及包含公式(I)化合物的制药组合物，以及治疗通过调节11-β-hsd-1介导的疾病的方法，该方法包括向哺乳动物投与公式(I)化合物的有效量。
• PHARMACEUTICAL COMPOUNDS
  申请人：Baker Stewart James

  公开号：US20120283257A1

  公开（公告）日：2012-11-08

  Thienopyrimidines of formula (Ia) or (Ib): wherein R 1 -R 3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  公式（Ia）或（Ib）的噻唑嘧啶类化合物：其中R1-R3具有此处所述的任何值，其药学上可接受的盐具有PI3K抑制剂活性，因此可用于治疗由与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和障碍，尤其是p110 delta亚型，如免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经障碍。还描述了合成这些化合物的过程。